Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus cCRT in advanced esophageal cancer
NCT06048926Phase 3Enrolling by invitation
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Jiangsu Provincial People's Hospital. Started Jul 2022; status: enrolling by invitation.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06048926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048926.